Is there a Link between Non Melanoma Skin Cancer and Hydrochlorothiazide?
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
AIMS: Here in we evaluated the association between the use of Hydrochlorothiazide (HCTZ) and the risk of NMSC both, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
BACKGROUND: Even though the use of HCTZ is not linked with the development of serious adverse drug reactions, non-melanoma skin cancer (NMSC) has been reported in patients treated with the drug in recent years, most likely due to its photosensitizing ability.
OBJECTIVE: To evaluate the statistically significant difference (P<0.05) in the development of NMSC between HCTZ users and non-users and the correlation (P<0.05) between HCTZ use and NMSC.
METHODS: We performed a retrospective study on patients referred to general practitioners who developed skin cancer or NMSC whether or not they were treated with antihypertensive drugs. Controls were matched with the test by age and sex. We calculated odds ratios (ORs) for skin cancer and NMSC associated with hydrochlorothiazide using conditional logistic regression.
RESULTS: We enrolled 19,320 patients in the present study, out of a total of 10,110 (52.3%) who were treated with antihypertensive drugs. Of 10,110 patients, 3,870 were treated with HCTZ (38.3%). During the study, we failed to report an increased risk of NMSC in HCTZ-treated vs. untreated patients. Gender stratification revealed an OR for NMSC of 1.36 for men and 0.56 for women. We did not find a dose-response relationship between HCTZ use and NMSC.
CONCLUSION: In the present study, we failed to report an association between the use of HCTZ and the development of NMSC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Current drug safety - 17(2022), 3 vom: 03., Seite 211-216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gallelli, Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0J48LPH2TH |
|---|
| Anmerkungen: |
Date Completed 29.07.2022 Date Revised 29.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1574886316666211103164412 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332702413 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332702413 | ||
| 003 | DE-627 | ||
| 005 | 20231225220116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1574886316666211103164412 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332702413 | ||
| 035 | |a (NLM)34732119 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is there a Link between Non Melanoma Skin Cancer and Hydrochlorothiazide? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.07.2022 | ||
| 500 | |a Date Revised 29.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a AIMS: Here in we evaluated the association between the use of Hydrochlorothiazide (HCTZ) and the risk of NMSC both, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) | ||
| 520 | |a BACKGROUND: Even though the use of HCTZ is not linked with the development of serious adverse drug reactions, non-melanoma skin cancer (NMSC) has been reported in patients treated with the drug in recent years, most likely due to its photosensitizing ability | ||
| 520 | |a OBJECTIVE: To evaluate the statistically significant difference (P<0.05) in the development of NMSC between HCTZ users and non-users and the correlation (P<0.05) between HCTZ use and NMSC | ||
| 520 | |a METHODS: We performed a retrospective study on patients referred to general practitioners who developed skin cancer or NMSC whether or not they were treated with antihypertensive drugs. Controls were matched with the test by age and sex. We calculated odds ratios (ORs) for skin cancer and NMSC associated with hydrochlorothiazide using conditional logistic regression | ||
| 520 | |a RESULTS: We enrolled 19,320 patients in the present study, out of a total of 10,110 (52.3%) who were treated with antihypertensive drugs. Of 10,110 patients, 3,870 were treated with HCTZ (38.3%). During the study, we failed to report an increased risk of NMSC in HCTZ-treated vs. untreated patients. Gender stratification revealed an OR for NMSC of 1.36 for men and 0.56 for women. We did not find a dose-response relationship between HCTZ use and NMSC | ||
| 520 | |a CONCLUSION: In the present study, we failed to report an association between the use of HCTZ and the development of NMSC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BCC | |
| 650 | 4 | |a Hydrochlorothiazide | |
| 650 | 4 | |a SCC | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a non-melanoma | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a skin cancer | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Hydrochlorothiazide |2 NLM | |
| 650 | 7 | |a 0J48LPH2TH |2 NLM | |
| 700 | 1 | |a Cione, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Siniscalchi, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Vasta, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Scaramuzzino, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Longo, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Muraca, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a De Sarro, Giovambattista |e verfasserin |4 aut | |
| 700 | 1 | |a G Sp Working Group |e verfasserin |4 aut | |
| 700 | 1 | |a Leuzzi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Gerace, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Scuteri, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Vasapollo, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Natale, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Zampogna, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Luciani, Filippo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g 17(2022), 3 vom: 03., Seite 211-216 |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:3 |g day:03 |g pages:211-216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574886316666211103164412 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 3 |b 03 |h 211-216 | ||